A clinical study conducted on 50 women in the age group of 18-45 years showed significant results in the treatment of polycystic ovary syndrome with the use of Fenugreek seed extract (Furocyst). The average BMI of the study population was 23.88 and had adequate hepatic, renal and haematological functions. At the time of enrolment, most of the patients had prolonged menstrual cycle (81%) and a few had irregular cycle (10%). Rest of the patients (10%) had primary infertilities.
Effect on the pregnancy
A significant % of population got pregnant during the treatment. It was observed, that 12% of the study population got pregnant. Three pregnancies were observed after 30 days, one each after 70 days, 84 days and 39 days of the treatment.
Effect on the ovary volume
As compared to baseline data, subjects showed significant reduction in ovary volume at the end of the study. Left ovary volume was decreased by 17.82% and right ovary volume was decreased by 28.25%.
Effect on the cysts
Enrolled subjects showed reduction in cyst size. Out of total 50 subjects, 46 % of the subjects showed reduced cyst size and 36% of the subjects showed complete dissolution of the cysts at the end of the study. A total of 6 patients got pregnant during the study. The overall % of the study population responding positively to fenugreek seed extract(Furocyst) comes out to be 94 %.
Effect on the menstrual cycle
There was significant improvement in menstrual cycle with consumption of the fenugreek seed extract. On completion of the last visit, 71% of patient had regular cycles, 19% patient reported prolonged cycle and approx. 10% reported primary infertility. None of the patient reported irregular cycle at the end of the fenugreek seed extract (Furocyst) dosing schedule.
Effect on Follicular Stimulating Hormone (FSH) and Haemoglobin (Hb)
A significant increase in follicular stimulating hormone levels was observed after 8 weeks as compared to baseline value (p =0.010). A significant increase in Hb levels was also observed on completion of the fenugreek dosing schedule as compared to baseline value (p=.000). The study showed Furocyst to be completely safe. No significant change in serum liver function, serum renal function and hemogram was observed.
Insulin directly acting on ovary, alone or/and along with LH can enhance ovarian androgen production. It indirectly also can increase androgen levels by reducing hepatic production of SHBG (sex hormone binding globulin) and IGFBP-1 (insulin like growth factor binding protein) and thus elevates free testosterone and free IGF-I, IGF-II levels (insulin like growth factor). Excess androgen impairs folliculogenesis resulting in menstrual disturbance, development of multiple cysts in ovary. Insulin resistance increases the risk of development of metabolic disorders including diabetes, hypertension, dyslipidemia and cardiovascular events in these women.
Furocyst improves insulin sensitivity and, in turn, regulates circulating androgen levels. It improves insulin-mediated glucose disposal in women with PCOS. Furocyst improved menstrual period in the study subjects and has a regulating effect of insulin on ovarian androgen biosynthesis, theca cell proliferation and endometrial growth. It regulates ovarian androgen production leading to disappearance or decrease in size and number of cysts. Increase in LH (Luteinizing Hormone)/FSH (Follicle-Stimulating Hormone) ratio has been reported in various studies conducted on PCOD patients. Because of a decreased level of follicle-stimulating hormone (FSH) relative to LH (Luteinizing Hormone), the ovarian granulosa cells cannot aromatize the androgens to estrogens, which lead to decreased estrogen levels and consequent anovulation. In the present study a significant decrease in LH/FSH ratio was observed, suggesting regulating effect of Furocyst (Fenugreek extract). For more information, please visit www.furocyst.com.
Furocyst is an innovative product (extracted and developed through a novel & innovative U.S. patented process) involving separations of active ingredients from the natural plant without affecting chemical properties of the active fractions. No chemicals are used. It is a natural and promising dietary supplement, clinically proven for management of Polycystic Ovary Syndrome (PCOS). It has got U.S.Patent. The details of the same are as follows:
US 8,754, 205 B2
United States Patent Authority
A novel process for the extraction of Furostanolic Saponins from Fenugreek Seeds.
Company Name: Conversations PR
Contact Person: Kiran Joshi